Hypercholesterolemia (Metabolic Disorder) - Drugs in Development, 2021

October 2021 | 329 pages | ID: H56542A89D0CEN
Global Markets Direct

Abstracts

Hypercholesterolemia (Metabolic Disorder) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Drugs In Development, 2021, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 17, 19, 6, 3, 24, 10 and 6 respectively. Similarly, the Universities portfolio in Phase 0, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Hypercholesterolemia - Overview
Hypercholesterolemia - Therapeutics Development
Hypercholesterolemia - Therapeutics Assessment
Hypercholesterolemia - Companies Involved in Therapeutics Development
Hypercholesterolemia - Drug Profiles
Hypercholesterolemia - Dormant Projects
Hypercholesterolemia - Discontinued Products
Hypercholesterolemia - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Hypercholesterolemia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Hypercholesterolemia - Pipeline by 3SBio Inc, 2021
Hypercholesterolemia - Pipeline by AD Pharmaceuticals Co Ltd, 2021
Hypercholesterolemia - Pipeline by Addpharma Inc, 2021
Hypercholesterolemia - Pipeline by Akcea Therapeutics Inc, 2021
Hypercholesterolemia - Pipeline by Alexion Pharmaceuticals Inc, 2021
Hypercholesterolemia - Pipeline by Amgen Inc, 2021
Hypercholesterolemia - Pipeline by Amryt Pharma Plc, 2021
Hypercholesterolemia - Pipeline by Arrowhead Pharmaceuticals Inc, 2021
Hypercholesterolemia - Pipeline by Astellas Pharma Inc, 2021
Hypercholesterolemia - Pipeline by AstraZeneca Plc, 2021
Hypercholesterolemia - Pipeline by Beijing Mabworks Biotech Co Ltd, 2021
Hypercholesterolemia - Pipeline by BioLingus AG, 2021
Hypercholesterolemia - Pipeline by CardioPharma Inc, 2021
Hypercholesterolemia - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2021
Hypercholesterolemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Hypercholesterolemia - Pipeline by JW Pharmaceutical Corp, 2021
Hypercholesterolemia - Pipeline by Kowa Co Ltd, 2021
Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co Ltd, 2021
Hypercholesterolemia - Pipeline by LIB Therapeutics LLC, 2021
Hypercholesterolemia - Pipeline by Lipigon Pharmaceuticals AB, 2021
Hypercholesterolemia - Pipeline by LipimetiX Development Inc, 2021
Hypercholesterolemia - Pipeline by Luckwel Pharmaceuticals Inc, 2021
Hypercholesterolemia - Pipeline by Luye Pharma Group Ltd, 2021
Hypercholesterolemia - Pipeline by Lyndra Therapeutics Inc., 2021
Hypercholesterolemia - Pipeline by Mab-Science (Hong Kong) Co Ltd, 2021
Hypercholesterolemia - Pipeline by Madrigal Pharmaceuticals Inc, 2021
Hypercholesterolemia - Pipeline by Medlab Clinical Ltd, 2021
Hypercholesterolemia - Pipeline by Merck & Co Inc, 2021
Hypercholesterolemia - Pipeline by NeuroBo Pharmaceuticals Inc, 2021
Hypercholesterolemia - Pipeline by Novartis AG, 2021
Hypercholesterolemia - Pipeline by Novo Nordisk AS, 2021
Hypercholesterolemia - Pipeline by Nyrada Inc, 2021
Hypercholesterolemia - Pipeline by OliPass Corporation, 2021
Hypercholesterolemia - Pipeline by Orient Pharma Co Ltd, 2021
Hypercholesterolemia - Pipeline by Precision Biosciences Inc, 2021
Hypercholesterolemia - Pipeline by Progenra Inc, 2021
Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals Inc, 2021
Hypercholesterolemia - Pipeline by RegenxBio Inc, 2021
Hypercholesterolemia - Pipeline by Repair Biotechnologies Inc, 2021
Hypercholesterolemia - Dormant Projects, 2021
Hypercholesterolemia - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hypercholesterolemia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021